论文部分内容阅读
来那度胺是一种新型的免疫调节药物,已被广泛应用于治疗多发性骨髓瘤,但其所致静脉血栓形成的副作用也越来越明显。当单独使用来那度胺治疗多发性骨髓瘤时,患者静脉血栓的发生率比较低,而其与地塞米松、化疗药物等联合使用治疗多发性骨髓瘤时,静脉血栓的发生率明显高于单独使用。来那度胺致多发性骨髓瘤患者静脉血栓形成的机制目前尚未完全阐明,国内外研究显示,其主要与内皮细胞功能紊乱、组织因子与磷脂酰丝氨酸暴露增加及体内的高凝状态相关。本文主要就来那度胺致多发性骨髓瘤患者静脉血栓形成的机制进行了简要综述。
Lenalidomide, a novel immunomodulatory drug, has been widely used in the treatment of multiple myeloma, but its side effects of venous thrombosis are more and more obvious. When lenalidomide alone is used to treat multiple myeloma, the incidence of venous thromboembolism is low, and the incidence of venous thromboembolism in patients with multiple myeloma when used in combination with dexamethasone and chemotherapy drugs is significantly higher than Use alone. The mechanism of lenalidomide in patients with multiple myeloma caused by venous thrombosis has not been fully elucidated at home and abroad, the study shows that its main and endothelial dysfunction, tissue factor and phosphatidylserine increased exposure and hypercoagulable state in vivo. This article briefly reviews the mechanism of levamisole-induced venous thrombosis in patients with multiple myeloma.